Skip to main content
OpenTrials

Clinical trial condition

Multiple Myeloma

Explore clinical trials studying Multiple Myeloma. Study availability and eligibility vary by location and protocol.

2,610 public trials 494 recruiting studies
Refine in advanced search Browse all conditions

Multiple Myeloma trial results

Completed

Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma

NCT02902965

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Fakultní nemocnice Brno Brno, Czechia
  • Fakultní nemocnice Hradec Králové Nový Hradec Králové, Czechia
  • Fakultní nemocnice Ostrava Ostrava-Poruba, Czechia
  • Všeobecná fakultní nemocnice v Praha Prague, Czechia
View all 33 locations
View Trial Details
Completed

A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers

NCT01587703

Conditions
Blood Protein Disorders, Bronchial Neoplasms, Carcinoma, +31 more
Locations
  • GSK Investigational Site Baltimore, Maryland, United States
  • GSK Investigational Site Boston, Massachusetts, United States
  • GSK Investigational Site Philadelphia, Pennsylvania, United States
  • GSK Investigational Site Nashville, Tennessee, United States
View all 17 locations
View Trial Details
Completed

Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma

NCT00918333

Conditions
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, +75 more
Locations
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • Mark O Hatfield-Warren Grant Magnuson Clinical Center Bethesda, Maryland, United States
  • Mayo Clinic Rochester, Minnesota, United States
View Trial Details
Completed

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma

NCT01478581

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • SITE-13 La Jolla, California, United States
  • SITE-5 Baltimore, Maryland, United States
  • SITE-4 Boston, Massachusetts, United States
  • SITE-8 Ann Arbor, Michigan, United States
View Trial Details
Completed

A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies

NCT03106428

Conditions
Acute Myeloid Leukemia, Blood Protein Disorders, Cardiovascular Diseases, +22 more
Locations
  • Research Site Los Angeles, California, United States
  • Research Site Denver, Colorado, United States
  • Research Site Atlanta, Georgia, United States
  • Research Site Chicago, Illinois, United States
View all 14 locations
View Trial Details
Completed

Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma

NCT02168101

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Oncology Hematology Care Cincinnati, Ohio, United States
  • Tennessee Oncology PLLC Nashville, Tennessee, United States
  • Texas Transplant Institute San Antonio, Texas, United States
View Trial Details
Completed

Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

NCT01049945

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • City of Hope Duarte, California, United States
  • Mayo Clinic in Florida Jacksonville, Florida, United States
  • University of Chicago Chicago, Illinois, United States
  • Mayo Clinic Rochester, Minnesota, United States
View Trial Details

Related conditions